Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Memory shield: turmeric and brain games may ward off cognitive decline in At-Risk seniors

NCT ID NCT07284316

Prevention Sponsor: Instituto Mexicano del Seguro Social Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of aerobic exercise, cognitive training, and turmeric (with black pepper) can prevent memory decline in adults aged 55-70 who have insulin resistance and self-reported memory concerns. Participants will follow a 24-week program, repeated after a year, and researchers will measure changes in thinking skills, insulin resistance, and markers of inflammation. The goal is to find a practical way to reduce dementia risk in a high-risk population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Minimum Age: 55 Years Maximum Age: 70 Years Sex: All Gender Based: No Accepts Healthy Volunteers: No Criteria: Inclusion criteria. * 1\. With 55-70 years of age. * 2\. They have self-reported cognitive concerns (ie, have answered "yes" to the question: "Do you feel like your memory or thinking skills have gotten worse recently?"). * 3\. The participant has insulin resistance measured with HOMA IR index \> 2.5. * 4\. They demonstrate functional independence in activities of daily living and instrumental activities of daily living. * 5\. They have symptoms or signs of underlying cognitive dysfunction without a diagnosis of dementia (ie, confirmed by a review of their health records and a Mini Mental State Exam \[MMSE\] score\> 24). * 6\. If the participant are a woman, one year after having gone through menopause. Exclusion Criteria: * 1\. With depression (score\> 15 according to the Center for Epidemiological Studies Depression Scale - Revised \[CESD-R\]). * 2\. With clinically significant neurological or psychiatric disorders (eg, Parkinson's, schizophrenia). * 3\. With a recent severe cardiovascular event (eg, myocardial infarction, stroke). * 4\. With a major orthopedic condition (eg, severe osteoarthritis). * 5\. With blood pressure that is unsafe for exercise (ie,\> 180/100 mmHg or \<100/60 mmHg). * 6\. With a severe visual or auditory impairment. * 7\. With an unwillingness to adhere to the intervention schedules. * 8\. Patients with active cancer, who are undergoing chemotherapy, radiotherapy, or other treatments aimed at eradicating cancer and who have been undergoing treatment during the last year. * 9\. Elimination: participants with incomplete data and who have not complied with the intervention by 80%.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Insulin Resistance subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive decline Insulin resistance Subjective cognitive impairment

Contacts and locations

Locations

  • Centro Medico Nacional Siglo XXI, unidad de investigación en epidemiología y servicio de salud.

    Mexico City, Cuauhtémoc, 06720, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.